Table 1. Baseline Characteristics of the Study Participants.
Characteristic | Participants, No. (%) | |
---|---|---|
Intervention (n = 132) | Control (n = 137) | |
Age, mean (SD), y | 48.5 (10.8) | 49.1 (12.9) |
Male | 62 (47.0) | 66 (48.2) |
Race | ||
White | 67 (50.8) | 68 (49.6) |
Black or African American | 61 (46.2) | 63 (46.0) |
Asian | 1 (0.8) | 4 (2.9) |
Native Hawaiian or other Pacific Islander | 1 (0.8) | 0 |
Other race | 2 (1.5) | 2 (1.5) |
Hispanic or Latino | 2 (1.5) | 4 (2.9) |
Not high school graduate | 29 (22.0) | 37 (27.0) |
Never married | 98 (74.2) | 85 (62.0) |
Lives in residential program or with caregiver | 76 (57.6) | 77 (56.2) |
Unable to work or receiving disability | 112 (84.9) | 120 (87.6) |
Health insurance | 130 (98.5) | 135 (98.5) |
Medicaid | 125 (94.7) | 129 (94.2) |
Medicare | 68 (51.5) | 67 (48.9) |
Regular physician | 126 (95.5) | 129 (94.2) |
Routine physical examination in the past year | 113 (85.6) | 122 (92.4) |
Psychiatric diagnoses | ||
Schizophrenia | 40 (30.3) | 41 (29.9) |
Schizoaffective disorder | 46 (34.9) | 32 (23.4) |
Bipolar disorder | 25 (18.9) | 42 (30.7) |
Major depression | 20 (15.2) | 18 (13.1) |
Other psychotic disorder | 1 (0.8) | 4 (2.9) |
History of alcohol or other substance use disordera | 69 (52.3) | 69 (50.4) |
All medications, mean (SD), No. | 9.4 (5.7) | 10.4 (5.4) |
Psychotropic medications, mean (SD), No. | 3.5 (1.9) | 3.6 (1.8) |
Antipsychotic | ||
Any | 106 (80.3) | 114 (83.2) |
Second generation | 86 (65.2) | 103 (75.2) |
Clozapine or olanzapine | 29 (22.0) | 34 (24.8) |
Lithium or mood stabilizer | 68 (51.5) | 82 (59.9) |
Antidepressant | 86 (65.2) | 88 (64.2) |
Psychiatric measures, mean (SD), score | ||
Behavior and Symptom Identification Scale–24b | 1.1 (0.7) | 1.2 (0.7) |
Center for Epidemiologic Studies Depression Scalec | 20.8 (11.8) | 19.9 (12.0) |
Cardiovascular risk factors, No.d | ||
1 | 14 (10.6) | 20 (14.6) |
2 | 37 (28.0) | 23 (16.8) |
3 | 39 (29.6) | 47 (34.3) |
4 | 33 (25.0) | 34 (24.8) |
5 | 9 (6.8) | 13 (9.5) |
Determined according to the Behavior and Symptom Identification Scale–24, the Addiction Severity Index, and diagnoses captured during medical chart abstraction.
Overall summary scores on the Behavior and Symptom Identification Scale–24 range from 0 to 4, with higher scores indicating greater severity of symptoms.
Scores on the Center for Epidemiologic Studies Depression Scale range from 0 to 60, with higher scores indicating more depressive symptoms; a score of 16 points is considered to be a cutoff point for depression.
Includes body mass index (calculated as weight in kilograms divided by height in meters squared) greater than or equal to 25, hypertension, diabetes, dyslipidemia, and tobacco smoking.